UCB (OTCMKTS:UCBJY) versus Cardiol Therapeutics (NASDAQ:CRDL) Critical Survey

UCB (OTCMKTS:UCBJY) and Cardiol Therapeutics (NASDAQ:CRDL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for UCB and Cardiol Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UCB	0	1	0	2	3.33
Cardiol Therapeutics	1	0	2	0	2.33

Cardiol Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 596.72%. Given Cardiol Therapeutics’ higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than UCB.

Profitability

This table compares UCB and Cardiol Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
UCB	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Volatility and Risk

UCB has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Valuation and Earnings

This table compares UCB and Cardiol Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UCB	$8.76 billion	6.28	$1.76 billion	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20 million	($0.28)	-4.36

UCB has higher revenue and earnings than Cardiol Therapeutics.

Summary

UCB beats Cardiol Therapeutics on 6 of the 11 factors compared between the two stocks.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.